CMV-TCR-T Cells for Refractory CMV Infection After HSCT

Allogeneic Hematopoietic Stem Cell Transplantation Clinical Trial

Official title: A Study of CMV-TCR-T Cells in the Treatment of Refractory CMV Viremia After HSCT

Status Recruiting

Clinical Trial Summary

This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.

Clinical Trial Description

CMV infection is a major and potentially life-threatening complication after allogenic hematopoietic stem cell transplantation (allo-SCT). Pharmacotherapy with ganciclovir and foscarnet remains the mainstay of treatment and has significantly improve clinical results, however, it is unsatisfactory owing to toxicity, limited efficacy and risk of developing resistance. In recent years, adoptive T cell therapy has been proposed as an alternative option for CMV infection after allo-SCT. However, patients with transplants from CMV-negative donors are at highest risk, and an adoptive therapy is missing because CMV-specific T cells are not available. CMV TCR-transduced donor-derived T Cells (CMV-TCR-T cells) is an attractive strategy to specifically redirect T-cell immunity toward CMV. In this prospective clinical phase I trial, we propose to evaluate the safety and efficacy of stem cell donor-derived CMV-TCR-T cells for patients with refractory CMV infection after allo-SCT. Donor derived CMV-TCR-T(HLA-A*1101\0201\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14, day 28). ;

Related Conditions & MeSH terms

• Allogeneic Hematopoietic Stem Cell Transplantation
• CMV Infection
• Cytomegalovirus Infections
• Infections

• NCT number: NCT05089838
• Study type: Interventional
• Source: Peking University People's Hospital
• Contact: Lanping Xu, PhD,MD
• Phone: 86-010-88324671
• Email: lpxu_0415@sina.com
• Status: Recruiting
• Phase: Phase 1
• Start date: January 6, 2021
• Completion date: October 2023